Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 80 years old, of any gender, who fully understand the study and are willing to sign a consent form to take part.
- People who have been diagnosed with a specific type of lymphoma called DLBCL that has a TP53 gene mutation, confirmed through a tissue sample (biopsy). This includes cases where DLBCL has developed from a slower-growing lymphoma.
- People who have not previously had any systemic (whole-body) treatment for their lymphoma. Prior radiotherapy to a specific area only is allowed.
- People who have at least one area of lymphoma that can be measured or assessed according to standard lymphoma guidelines (Lugano 2014 criteria).
- People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning largely able to carry out daily activities, with confirm with trial site if unsure which category applies).
- People expected to live for at least 3 months.
- People whose bone marrow, liver, and kidneys are functioning adequately.
Who may not be able to join:
- People whose DLBCL is associated with Hodgkin lymphoma, T-cell lymphoma, other non-B-cell lymphomas, or a condition called Richter transformation.
- People whose lymphoma has spread to the brain or spinal cord (central nervous system).
- People who have previously been treated with a type of drug called an XPO1 inhibitor.
- People who have a medical reason why they cannot take any of the drugs used in this trial's treatment combination.
- People with chronic active hepatitis B or active hepatitis C infection. People with certain hepatitis B or C markers in their blood may still be considered, provided virus levels are below specified limits and, where required, they are receiving anti-hepatitis B medication (confirm with trial site for details).
- People who are HIV-positive or have AIDS.
- People who have difficulty swallowing tablets, or who have a condition affecting how the body absorbs food or medication through the digestive system.
- Women who are pregnant or breastfeeding, and people of childbearing potential who do not wish to use contraception during the study.
- People with a mental illness or anyone unable to provide informed consent.
- Anyone considered unsuitable to participate based on the judgement of the trial doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: QingQing Cai, MD. PhD., Sun yat-sen university cancer cente
Phone: 0086-20-87342823
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete response rate (CRR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.